PRF Technologies (PRFX) Cash & Current Investments (2019 - 2025)

PRF Technologies (PRFX) posted quarterly Cash & Current Investments of $4.1 million for Q4 2025, down 2.82% year-on-year from $4.3 million in Q4 2024, and up 18.52% on a QoQ basis from $3.5 million in Q2 2025.

PRF Technologies (PRFX) Cash & Current Investments (2019 - 2025) Analysis & Trends

PRF Technologies (PRFX) has reported Cash & Current Investments for 7 consecutive years, with $4.1 million the latest figure, recorded in Q4 2025.

  • Quarterly Cash & Current Investments fell 2.82% year-over-year to $4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.1 million (down 2.82% YoY) and the FY2025 annual result came in at $4.1 million, down 2.82% from the prior year.
  • Cash & Current Investments improved to $4.1 million in Q4 2025 per PRFX's latest filing, from $3.5 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for PRFX reached as high as $19.4 million in Q1 2021 and fell as low as $2.8 million in Q2 2024.
  • A 5-year average of $10.3 million and a median of $8.2 million in 2023 frame the typical range for Cash & Current Investments.
  • Annual changes were most pronounced in 2021 — Cash & Current Investments surged 3137.09% — and 2023, when it slumped 55.57%.
  • Year by year, Cash & Current Investments stood at $16.5 million in 2021, then tumbled by 38.44% to $10.2 million in 2022, then slipped by 21.17% to $8.0 million in 2023, then tumbled by 46.91% to $4.3 million in 2024, then decreased by 2.82% to $4.1 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods registered $4.1 million, $3.5 million, and $4.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Current Investments (Qtr)
1 Haleon 89.55 Bn 87.69 Bn - 1.86 Bn
2 Teva Pharmaceutical Industries 36.00 Bn 32.26 Bn 1.97 Bn 3.74 Bn
3 Zoetis 32.59 Bn 30.65 Bn 1.62 Bn 1.94 Bn
4 Takeda Pharmaceutical 27.52 Bn 23.45 Bn 4.39 Bn 4.06 Bn
5 United Therapeutics 23.07 Bn 20.91 Bn 648.10 Mn 2.15 Bn
6 RedHill Biopharma 21.48 Bn 21.48 Bn - -
7 Viatris 20.28 Bn 18.47 Bn 1.16 Bn 1.80 Bn
8 Neurocrine Biosciences 17.78 Bn 16.47 Bn 800.70 Mn 1.32 Bn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 428.00 Mn
10 PRF Technologies 706,290.59 -3.43 Mn - 4.14 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 4.14 Mn
Jun 30, 2025 3.49 Mn
Dec 31, 2024 4.26 Mn
Jun 30, 2024 2.79 Mn
Mar 31, 2024 4.33 Mn
Dec 31, 2023 8.03 Mn
Sep 30, 2023 7.56 Mn
Jun 30, 2023 6.16 Mn
Mar 31, 2023 8.15 Mn
Dec 31, 2022 10.18 Mn
Sep 30, 2022 12.98 Mn
Jun 30, 2022 13.87 Mn
Mar 31, 2022 16.57 Mn
Dec 31, 2021 16.54 Mn
Sep 30, 2021 18.34 Mn
Jun 30, 2021 17.80 Mn
Mar 31, 2021 19.44 Mn
Dec 31, 2020 15.68 Mn
Sep 30, 2020 17.72 Mn
Jun 30, 2020 550,000.00